查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019494

2026-2034年全球人類微生物組市場規模、佔有率、趨勢和成長分析報告

Global Human Microbiome Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 168 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計人類微生物組市場將從 2025 年的 22.9 億美元成長到 2034 年的 128.8 億美元，2026 年至 2034 年的複合年成長率為 21.16%。

由於微生物在人類健康中作用的研究不斷深入，全球人類微生物組市場正經歷快速成長。人類微生物組與多種疾病相關，包括胃腸道疾病、代謝性疾病和免疫系統調節。人們對腸道環境重要性的認知不斷提高，以及對益生菌和基於微生物組的治療方法的需求不斷成長，正在推動市場擴張。此外，定序技術的進步也使得人們能夠更深入地了解微生物群落。

關鍵成長要素包括微生物組研究投入的增加，以及微生物組相關產品在醫療保健和營養領域的應用不斷拓展。製藥和生技公司正致力於開發針對多種疾病的微生物組標靶治療方法。個人化醫療和預防醫學的日益普及也促進了市場成長。此外，研究機構與產業相關人員之間的合作正在加速該領域的創新。

預計未來人類微生物組市場將顯著成長，這主要得益於持續的研發和技術進步。標靶微生物組療法和診斷技術的開發將拓展其臨床應用。在新興市場，健康意識的提高和醫療基礎設施的改善有望創造新的機會。此外，監管的完善和標準化也將促進基於微生物組產品的商業化。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球人類微生物組市場：依部位分類

  • 市場分析、洞察與預測
  • 消化道
  • 肺
  • 生殖腔
  • 皮膚
  • 其他部分

第5章：全球人類微生物組市場：依應用分類

  • 市場分析、洞察與預測
  • 治療
  • 診斷

第6章 全球人類微生物組市場：依疾病分類

  • 市場分析、洞察與預測
  • 感染疾病
  • 消化系統疾病
  • 內分泌和代謝疾病
  • 癌症
  • 中樞神經系統疾病
  • 其他疾病

第7章 全球人類微生物組市場：依產品分類

  • 市場分析、洞察與預測
  • 製藥
  • 補充
  • 診斷測試
  • 其他產品

第8章 全球人類微生物組市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Biohm Technologies
    • BioGaia
    • Biome Diagnostics
    • BiomeBank
    • Ferring
    • Intralytix
    • OptiBiotix
    • Pendulum Therapeutics
    • Prescient Metabiomics
    • Seres Therapeutics
簡介目錄
Product Code: VMR11215790

The Human Microbiome Market size is expected to reach USD 12.88 Billion in 2034 from USD 2.29 Billion (2025) growing at a CAGR of 21.16% during 2026-2034.

The global human microbiome market is experiencing rapid growth due to increasing research on the role of microorganisms in human health. The human microbiome is linked to various conditions, including gastrointestinal disorders, metabolic diseases, and immune system regulation. Growing awareness about the importance of gut health and the rising demand for probiotic and microbiome-based therapies are driving market expansion. Additionally, advancements in sequencing technologies are enabling deeper insights into microbial communities.

Key growth drivers include increasing investments in microbiome research and the expanding applications of microbiome-based products in healthcare and nutrition. Pharmaceutical and biotechnology companies are focusing on developing microbiome-targeted therapies for various diseases. The rising popularity of personalized medicine and preventive healthcare is also contributing to market growth. Furthermore, collaborations between research institutions and industry players are accelerating innovation in this field.

Looking ahead, the human microbiome market is expected to grow significantly with ongoing research and technological advancements. The development of targeted microbiome therapies and diagnostics will expand clinical applications. Emerging markets are likely to offer new opportunities due to increasing health awareness and improving healthcare infrastructure. Additionally, regulatory advancements and standardization will support the commercialization of microbiome-based products.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Site

  • Digestive Tract
  • Lung
  • Reproductive Cavity
  • Skin
  • Other Sites

By Application

  • Therapeutics
  • Diagnostics

By Disease

  • Infectious Disease
  • Gastrointestinal Disease
  • Endocrine And Metabolic Diseases
  • Cancer
  • Central Nervous System Disorder
  • Other Diseases

By Product

  • Drugs
  • Supplements
  • Diagnostic Tests
  • Other Products

COMPANIES PROFILED

  • Archer Daniels Midland Company, , Biohm Technologies, BioGaia, Biome Diagnostics, BiomeBank, Ferring, Intralytix, OptiBiotix, Pendulum Therapeutics, Prescient Metabiomics, Seres Therapeutics
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN MICROBIOME MARKET: BY SITE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Site
  • 4.2. Digestive Tract Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Reproductive Cavity Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Skin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Other Sites Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HUMAN MICROBIOME MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HUMAN MICROBIOME MARKET: BY DISEASE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Disease
  • 6.2. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Gastrointestinal Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Endocrine And Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Central Nervous System Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HUMAN MICROBIOME MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Product
  • 7.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Supplements Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Diagnostic Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Other Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HUMAN MICROBIOME MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Site
    • 8.2.2 By Application
    • 8.2.3 By Disease
    • 8.2.4 By Product
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Site
    • 8.3.2 By Application
    • 8.3.3 By Disease
    • 8.3.4 By Product
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Site
    • 8.4.2 By Application
    • 8.4.3 By Disease
    • 8.4.4 By Product
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Site
    • 8.5.2 By Application
    • 8.5.3 By Disease
    • 8.5.4 By Product
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Site
    • 8.6.2 By Application
    • 8.6.3 By Disease
    • 8.6.4 By Product
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL HUMAN MICROBIOME INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Biohm Technologies
    • 10.2.2 BioGaia
    • 10.2.3 Biome Diagnostics
    • 10.2.4 BiomeBank
    • 10.2.5 Ferring
    • 10.2.6 Intralytix
    • 10.2.7 OptiBiotix
    • 10.2.8 Pendulum Therapeutics
    • 10.2.9 Prescient Metabiomics
    • 10.2.10 Seres Therapeutics